## Statement of Cash Flows -

## Peptinovo Biopharma Inc

January 1-December 31, 2023

| FULL NAME   | TOTAL           |
|---|-----------------|
| OPERATING ACTIVITIES  |                 |
| Net Income  | -2,832,689.52   |
| Adjustments to reconcile Net Income to Net Cash provided by operations:           |                 |
| 20000 Accounts Payable  | 10,943.72       |
| Credit card old   | -14,451.63      |
| Direct Deposit Payable  |                 |
| Loan Cantilever   |                 |
| Loan Ehlert   |                 |
| Loan Homan 10   |                 |
| Loan Stinson  |                 |
| Loan Tokarz   |                 |
| Patents   | -11,078.18      |
| Payroll Liabilities:Federal Taxes (941/944)                                       | 813.79          |
| Payroll Liabilities:Federal Unemployment (940)                                    |                 |
| Payroll Liabilities:MI Income Tax   | -498.27         |
| Payroll Liabilities:MI Unemployment Tax   | 173.22          |
| Total for Adjustments to reconcile Net Income to Net Cash provided by operations: | -\$14,097.35    |
| Net cash provided by operating activities   | -\$2,846,786.87 |
| INVESTING ACTIVITIES  | 0               |
| FINANCING ACTIVITIES  |                 |
| 30100 Stock   | 450.00          |
| Convertible Debt/Bridge 2022  | 3,013,400.00    |
| SAFE Series 1   | 123,700.00      |
| Net cash provided by financing activities   | \$3,137,550.00  |
| NET CASH INCREASE FOR PERIOD  | \$290,763.13    |
| Cash at beginning of period   | \$59,735.12     |
| CASH AT END OF PERIOD   | \$350,498.25    |

## Statement of Cash Flows -

## Peptinovo Biopharma Inc

January 1-December 31, 2024

| FULL NAME   | TOTAL           |
|---|-----------------|
| OPERATING ACTIVITIES  |                 |
| Net Income  | -4,803,155.21   |
| Adjustments to reconcile Net Income to Net Cash provided by operations:           |                 |
| 11000 Accounts Receivable   |                 |
| 20000 Accounts Payable  | 913,136.78      |
| Credit card old   | -109.90         |
| Credit card pnc xx8075  | 41,733.20       |
| Direct Deposit Payable  |                 |
| loan Agley  |                 |
| Loan CIF2   | 26,000.00       |
| Loan Homan 10   | 150,000.00      |
| Loan MEF 10   | 37,000.00       |
| Loan MRP-F19  | 2,000,000.00    |
| Loan Stinson  | -125,000.00     |
| Loan Tokarz   |                 |
| Michigan Department of Treasury Payable   |                 |
| Payroll Liabilities:Federal Taxes (941/944)                                       | 418.40          |
| Payroll Liabilities:Federal Unemployment (940)                                    | 42.00           |
| Payroll Liabilities:MI Income Tax   | -164.53         |
| Payroll Liabilities:MI Unemployment Tax   | -87.22          |
| Peptinovo Australia   | -732,000.00     |
| Total for Adjustments to reconcile Net Income to Net Cash provided by operations: | \$2,310,968.73  |
| Net cash provided by operating activities   | -\$2,492,186.48 |
| INVESTING ACTIVITIES  |                 |
| Security Deposits   | -3,109.11       |
| Net cash provided by investing activities   | -\$3,109.11     |
| FINANCING ACTIVITIES  |                 |
| 30100 Stock   | 16,744.25       |
| Convertible Debt/Bridge 2022  | -3,755,900.00   |
| SAFE Series 1   | -2,001,857.64   |
| Series A1 equity  | 8,216,457.64    |
| Series A1 pending close   | 100,000.00      |
| Net cash provided by financing activities   | \$2,575,444.25  |
| NET CASH INCREASE FOR PERIOD  | \$80,148.66     |
| Cash at beginning of period   | \$350,498.25    |
| CASH AT END OF PERIOD   | \$430,646.91    |